tradingkey.logo

Integra Lifesciences Holdings Corp reports results for the quarter ended March 31 - Earnings Summary

ReutersMay 5, 2025 1:31 PM
  • Integra Lifesciences Holdings Corp IART.OQ reported quarterly adjusted earnings of 41 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of 55 cents. The mean expectation of eleven analysts for the quarter was for earnings of 43 cents per share. Wall Street expected results to range from 41 cents to 45 cents per share.

  • Revenue rose 3.7% to $382.65 million from a year ago; analysts expected $381.17 million.

  • Integra Lifesciences Holdings Corp's reported EPS for the quarter was a loss of 33 cents​.

  • The company reported a quarterly loss of $25.29 million.

  • Integra Lifesciences Holdings Corp shares had fallen by 23.4% this quarter and lost 25.7% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had fallen by about 22.3% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 6 "hold" and 4 "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "hold"

  • Wall Street's median 12-month price target for Integra Lifesciences Holdings Corp is $22.50

This summary was machine generated from LSEG data May 5 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Mar. 31 2025

0.43

0.41

Missed

Dec. 31 2024

0.86

0.97

Beat

Sep. 30 2024

0.39

0.41

Beat

Jun. 30 2024

0.62

0.63

Beat

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI